Oncimmune Holdings ( (GB:ONC) ) has provided an announcement.
Oncimmune Holdings plc has announced its intention to appoint administrators and suspend trading of its shares on AIM due to its inability to secure a buyer for its subsidiary, Oncimmune Germany GmbH, or raise necessary capital for short-term funding. The decision to enter administration is aimed at preserving the business’s value for creditors, with Alvarez & Marsal Europe LLP set to be appointed as administrators.
More about Oncimmune Holdings
Oncimmune is a precision medicine company focused on analyzing immune interactions through autoantibody profiles. It partners with global pharmaceutical and biotech companies, as well as contract research organizations, to discover novel biomarkers for targeted therapies in immune-mediated diseases. The company is headquartered in the UK, with facilities in Germany and business development teams in the US and Europe.
YTD Price Performance: -92.06%
Average Trading Volume: 405,428
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.27M
Learn more about ONC stock on TipRanks’ Stock Analysis page.